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As heart transplantation has evolved as a treatment for 
refractory heart failure, it has been recognized that early 
postoperative right heart failure is a common occurrence 
associated with substantial morbidity and mortality (l-3). 
Elevations of transpulmonaty pressure gradient and pulmo- 
nary vascular esistance are common in patients with chronic 
left heart failure, and their persistence through the peritrans- 
ptantation period can lead to right ventricular failure, partic- 
ularly if prolonged ischemia has occurred uring harvesting 
and transportation f the donor organ. Severe, fixed elevation 
of transpuhuonary pressure gradient or pulmonaty vascular 
resistance istherefore considered acontraindication toortho. 
topic heart transplantation. The immediate response of the 
pulmonary circulation to intravenous vasodilators, such as 
nitroprusside (4) amrinone (5) and prostaglandin E, (6), has 
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but did with nitric oxide, 
been used to identify patients at acceptable risk for transplan- 
tation, but the effectiveness of these agents in predicting the 
reversibility of pulmonary vasoconstriction is limited by their 
systemic hypotensive effects. 
Nitric oxide, an endothelium-derived relaxing factor (7) 
produced from L-arginine by endothelial nitric oxide syntbase 
(8) has an in viva half-life of 111 to 130 ms (9). Inhaled nitric 
oxide has been shown to reverse pulmonary vasoconstriction in 
hypoxic lambs (10) and pediatric patients with congenital heart 
disease complicated by pulmonary hypertension (11). In adults 
with pulmonary hypertension due to the adult respiratory 
distress yndrome, inhaled nitric oxide decreases pulmonary 
vascular esistance without altering systemic arterial pressure 
(l&13). It has been demonstrated that in patients with pulmo- 
nary vascular disease; inhaled nitric oxide also causes a reduc- 
tion in pulmonary vascular resistance (14,15), accompanied by 
an improvement in right ventricular performance, asindicated 
by an increase in stroke volume despite a decrease in right 
ventricular end-diastolic pressure (14). 
To assess the potential role of inhaled nitric oxide in 
identifying reversible pulmonary vasoconstriction in patients 
with severe heart failure referred for heart ransplantation, 
we compared its effects on transpulmonary p essure gradient, 
pulmonary vascular resistance and systemic arterial pressure 
with those of intravenous nitroprusside. 
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Outcome 
1 Siw DCM 1v 0.17 Died, not listed for transplantation 
2 49/M DCM 111 0.25 Transplantation performed 
3 .77/M DCM IV 0.12 Transplantation performed 
4 50/M CAD IV 0.23 Died 4 weeks after transplantation 
(renal, hepatic failure) 
5 S4lM CAD IV 0.13 Transplantation performed 
6 37/M CAD 111 0.18 Awaiting transplant 
7 SO/M CAD 111 0.15 Awaiting transplant 
8 W/M CAD 111 0.17 Awaiting transplant 
9 S2iM DCM 111 0.10 Transplantation performed 
IO 57/F HCMIDCM IV o.Kl Transplantation performed 
II 49/M DC 111 0. I7 Transplantation performed 
12 t13ik4 CA 111 t1.14 CABG 
I3 4VM DCM 111 II.27 Awaiting transplant 
I4 45/M DCM SV 11SlY Died awaiting transplant 
15 S’NF DCM 111 0.10 Awaiting transplant 
I6 53/M DCM III 0.17 Awaiting transplant 
Mean Sf 0. I6 
SEM 2 0.02 
CABS = coronary artery bypass grafting: CAD = curmutry artery disease; KM = dilated cardiomyopathy; Diagn = 
diagnosis; F = female; HCM = hypertrophic cardiomyopathy: LVEF = left ventricular ejection fraction; M = male; 
NYHA class = New York Heart Association functional class: PI = patient. 
atients. The study group included 13 men and 3 
I 2 years) with chronic New Yor 
A.ssociation class III or IV heart failure who were referred to 
the Massachusetts General Hospital for consideration ofheart 
transplantation (Table 1). The cause of heart failure was 
dilated cardiomyopathy in nine patients, coronary artery dis- 
ease in six and progression of hypertrophic cardiomyopathy to 
ventricular dilation and systolic dysfunction i one patient. No 
patient had a history of primary pulmonary disease, and the 
results of pulmonary function testing were consistent with 
chronic left heart failure, showing amild restrictive pattern and 
a mild decrease in diffusion capacity (16). All patients were 
treated with digoxin, diuretic drugs and vasodilators, and three 
(Patients 1,9 and 15) were treated with amiodarone for atrial 
or ventricular arrhythmias. Radionuclide l ft ventricular ejec- 
tion fraction was 0.16 f 0.02 (range 0.09 to 0.27). Patients 1,2 
and 14 had chronic atrial fibrillation, and Patient 15 had a 
ventricular paced rhythm; the remaining 12 patients were in 
sinus rhythm. The study protocol was approved by the Sub- 
committee on Human Studies of the Massachusetts General 
Hospital, and written informed consent was obtained from all 
patients. 
emodynamic measurements. Digoxin, diuretic drugs and 
vasodilators were discontinued 12 to 24 h before catheteriza- 
tion, and amiodarone therapy was continued. No premedica- 
tion was administered. Right heart catheterization was per- 
formed by way of the internal jugular vein with a triple-lumen 
balloon-tipped catheter. Systemic arterial pressure was mea- 
sured from a radial artery cannula or from the side arm of a 
femoral artery introducer. 
The following hemodynamic variables were recorded: heart 
rate, right atrial pressure, pulmonary artery pressure, pulmo- 
nary capillary wedge pressure and systemic arterial pressure. 
Cardiac output was determined by the Pick oxygen technique. 
Q,xygen consumption was measured with an 
consumption monitor (Waters Associates). Derived hemody- 
namic variables were calculated using the following formulas: 
Cardiac index (liters/min per m”) = Cardiac output/Body 
surface area; Transpulmonary pressure gradient (mm Hg) = 
ivlean pulmonary artery pressure - Pulmonary capillary wedge 
pressure; Stroke volume index (ml/m2) = Cardiac index/Heart 
rate; Right ventricular stroke work index (g-m/m2) = (0.0136) 
(Mean pulmonary artery pressure - Right atrial pressure)(Stroke 
volume index); Left ventricular stroke work index (g-m/m’) = 
(O.O136)(Mean systemic arterial pressure - Pulmonary capillary 
wedge pressure)(Stroke volume index); Systemic vascular resis- 
tance (dynesscm-‘) = 8O(Mean systemic arterial pressure - 
Right atrial pressure)/Cardiac output; Pulmonary vascular resis- 
tance (dynesscm-“) = 80(Transpulmonary p essure gradient)/ 
Cardiac output. 
Nitric oxide delivery. Nitric oxide gas (800 ppm in nitrogen 
[NJ) (Airco) was mixed with room air with the use of a 
standard low flow blender (Bird Blender) and then titrated 
with 100% oxygen using standard high flow rotameters 
(Timeter Instruments) to achieve a mixture of >90% oxygen 
with 20,40 or 80 ppm nitric oxide and the remhinder Np The 
mixture was then introduced into a non-rebreathing circuit 
consisting of large-bore aerosol tubing and a modified con- 
tinuous positive airway pressure mask (Respironics Inc.). 
The inspired concentration of nitric oxide and nitrogen 
dioxide was measured by chemiluminescence (17) (model 141% 
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T&le 2 Acute Hcme@amic Effects of Oxygen, Inhaled Nitric Oxide and Nitroprusside 
NO (aa ppm) Nitroprussidc 
Baseline 02 +02 0, to2 
Heart rate (bcats/min) 93 + 6 9026 96 t 6 9926 98 ‘t 7 
h(ean systemic arterial pressure (mm Hg) PAZ2 87 t 2 89 z 2 YO’2 68 _c I’?$ 
Right atrial pressure (mm Hg) 922 10r2 852 9t2 -I-+ I”?$ 
Mean putmonary artery pressure (mm Hg) 38 -c 3 37 2 3 39 ‘+ 2 38 t 4 19 5 3*+* 
Pdrnonaty capillary wedge pressure (mm Hg) 2523 26 t 2 32 r 2*$ 26 5 3 9 ? 2*‘rl 
Transpuhnonary pressure gradient (mm Hg) 14 4 2 11 t I* 7%-l** II ?2* IO c I*? 
Cardiac in&x (IiWmin per m’) 2.1 t 0.2 2.1 c 0.1 2.3 r 0.2 “._ 77+0? - ._ 2.Y t 0.3’1% 
Stroke volume index (ml/m’) 23 -c 2 24 + 2 24 I? 2 *_ 73 * P _ 7 30 2 4 
RV stroke work index (g-m/m’) 921 921 IO c 1 921 72 Ii 
LV struke work index (g-m/m”) 19 ” 2 20 ” 2 I9 22 ?I) _+ 2 23 rt 2*? 
Systemic vascular resistance (dynes%*m -s) 1,648 + 1,493 1,649 + 119 1,625 t I21 I .692 + 144 1,121 t 14lW$ 
Pulmonary vascular &stance (dynes-sem “) 323 + 64 256 + 4l* I39 ?I I.$*$ 264 C! 49” I69 ? 31)4t$ 
PVWSVR 0.19 L 003 0. IS f 0.02 0.09 It 0.01 “I 0. IS I? 0.03 0.15 L o.ot 
Oxygen saturation (a) 94 c 2 9YzI I* 992 I* lot) 2 1* YY”_ 1’ 
*p < 0.05 wsus baseline. tp < O.(1S nitroprussidc versus nitric oxide (NO). $p < 0.05 versus previous period uloxygcn (0,). Data are prcscnted irs nlcnn value -C 
SEM. LV 1 left ventricular: PVR = pulmomuy vascular rcsistancc; RV = right ventricular; SVR = systemic v;rsWlar resistnncc. 
ThermoEnvironmental Instruments Inc.) and that of oxygen by 
polarimetry (Hudson Oxygen Meter). The total gas flow rate 
was maintained at 45 liters/min, a level that reduced the nitric 
oxide residence time within the breathing circuit and, hence, 
the time for the oxidation of nitric oxide to nitrogen dioxide. 
Nitrogen dioxide was not measurable in the expired gas at any 
dose of nitric oxide. Exhaled gases were scavenged and dis- 
carded to the atmosphere. Blood methemoglobin levels were 
determined spectrophotometrically (18) at baseline and during 
the inhalation of 80 ppm nitric oxide. 
Study pmtucol. All measurements were made with the 
patient supine and wearing a face mask. Hemodynamic data 
were obtained during a baseline period with the patient 
inhaling room air; during inhalation of >90% oxygen; during 
inhalation of 20, 40 and 80 ppm nitric oxide in addition to 
>!#I% oxygen; during another period of >90% ovgen; and 
during the intravenous administration of nitroprusside in ad- 
dition to the inhalation of z+JO% oxygen. We administered 
>9O$G oxygen during nitroprusside infusion to avoid hypox- 
emia due to intrapulmonary shunting. To allow valid compar- 
isons among baseline, nitroprusside and nitric oxide periods, 
we administered >90% oxygen throughout the study protocol. 
The dosage of nitroprusside was titrated upward until a systolic 
arterial pressure of 85 mm Hg, a mean pulmonary artery 
pressure of 20 mm Hg or a maximal dose of 500 @min was 
achieved. Hemodynamic measurements were obtained 5 min 
after the dose of nitric oxide was altered or 5 min after the 
desired dose of nitroprusside was reached. The total duration 
of nitric oxide administration to each patient was -40 min. 
Statistics. Results are expressed as mean value -C SEM. A 
two-way analysis of variance with subsequent comparisons of 
group means by the Newman-Keuls test was used for compar- 
isons among the l.atment periods of room air, oxygen, 80 ppm 
nitric oxide with oxygen and nitroprusside with oxygen, as well 
as for evaluation of the dose response to 0 to 80 ppm of nitric 
oxide. Preoperative and postoperative hemodynamic variables 
in those patients who underwent transplantation were com- 
pared by paired Student t testing. A linear regression was used 
to compare the changes in pulmonary vascular resistance 
produced by nitric oxide with those observed after transplan- 
tation. A p value < 0.05 was considered sigtlificant. 
Mrememts, Right atrial pressure was elevated 
as were mean pulmonary artery pressure at 
38 -C 3 mm Hg and pulmonary capillary wedge pressure at 25 2 
3 mm Hg (Table 2). Cardiac index was depressed at 2.1 Ir 0.2 
liters/min per m’. Pulmonary vascular resistance was elevated at 
323 t 64 dynesscm-“. 
Effects of > oxygen. During inhalation of >90% oxy- 
gen, arterial oxygen saturation increased from 94 Z!I 2% to 
99 I- i% (p < 0,05), transpulmonary pressure gradient decreased 
from 14 2 2 to I1 2 1 mm Hg (p < O.OS), and pulmonary vascular 
resistance decreased from 323 + 64 to 256 2 41 dynesscm-” 
(p < 0.05) (Table 2). There was no effect on mean systemic 
arterial pressure or systemic vascular resistance. There were no 
significant differences in hemodynamic variables between the two 
>90% oxygen periods. 
Effects of nitric oxide. With the Jddition of 80 ppm nitric 
oxide to >90% oxygen, mean pulmonary artery pressure was 
unchanged, but pulmonary capillary wedge pressure increased 
from 26 ,C 2 to 32 2 2 mm Hg (p < 0.05) (Table 2). An 
increase in pulmonary capillary wedge pressure ~5 mm Hg was 
observed in 9 of the 16 patients (Patients 1 to 3,5 to 8, 10, 16). 
Transpulmonary pressure gradient decreased from 11 2 1 to 
7 +- 1 mm Hg (p < 0.05), and pulmonary vascular resistance 
decreased from 256 + 41 to 139 I!I 14 dynesscan-” (p e 0.05, 
Fig. 1A). Cardiac output, mean systemic arterial pressure and 
systemic vascular resistance were unchanged. The ratio of 
pulmonary vascular resistance to systemic vascular resistance 
i 
l@we 2. Relation between dose of nitric oxide and pulmonary 
vascular rcsistancc (PVR) IA) and pulmonary capillary wedge pressure 
(PCWP) (B). Data are exprcsscd as mean value 5 SEM. ‘rp c 0.05 
versus oxygen alone. #p < 0.05 versus 20 and 40 ppm nitric oxide. 
PPM = parts per million hy volume. 
1. A, Pulmonary vascular resistance (PVR) during oxygen 
itdministrarion andafter the addition of 80 ppm nitric oxide in each of 
the 16 patients. B, Pulmonary vascular resistance during oxygen 
administrA_m and with the maximal dose al nitroprnsside in each uf 
the I6 patients. The mean value ( and SEM are also shown. 
decreased from 0,15 t 0.02 to 0.09 t 0.01 with nitric oxide 
(p ==I 0.01). 
The effects of nitric oxide dosage on pulmonary vascular 
resistance and pulmonary capillary wedge pressure are shown 
in Figure 2, A and B, respectively. The maximal reduction of 
pulmonary vascular resistance was seen at 80 ppm, although an 
effect was observed with doses of 20 and 40 ppm. Pulmonary 
capillav wedge pressure increased with a dose of 20 ppm of 
nitric oxide; there was no further significant increase with 
doses of 40 or 80 ppm. 
Effects uf nilropmsside. With the addition of nitroprusside 
(214 t, 43 Fg!min) to >90% oxygen, mean pulmonary artery 
pressure decreased from 38 f 4 to 19 2 3 mm Hg (p -C O.Ol), 
and pulmonary capillary wedge pressure decreased from 26 4 
3 to 9 2 2 mm Hg (p -=c 0.01) (Table 2). Transpulmonary 
pressure gradient did not change, but cardiac index increased 
frown 2.2 2 0.2 to 2-Y It 0.3 litcrs/min per n? (p < 0.05), and 
pulmonary vascular esistance decreased from 264 4 49 to 
169 2 30 dynesscm ”’ (p -C 0.05) (Fig. 1B). Mean systemic 
arterial pressure decreased from 90 + 2 to 68 + I mm Hg (p < 
0.01). The dosage of nitroprusside was limited to <SOtI pgfmin 
by a decrease in systemic arterial pressure in 7 of the 16 
patients (Patients I,5 and 10 to 14). The ratio of pulmonaq 
vascular resistance to systemic vascular resistance did not 
change. 
Comparison of the erects of nitric oxide and nitruprusside, 
Kight atrial, mean pulmonary artery and pulmonary capillary 
wedge pressure were all lower during administration f nitro- 
prusside than during administration f nitric oxide. However, 
both transpulmonary pressure gradient and pulmonary vascu- 
lar resistance decreased to a greater extent with nitric oxide 
than with nitroprusside. Mean systemic arterial pressure was 
lower with nitroprusside, aswas systemic vascular resistance. 
The ratio of pulmonary vascular resistance tosystemic vascular 
resistance was lower with nitric oxide than with nitroprusside. 
Side effects. No side effects were observed uring nitric 
oxide or nitroprusside administration. Despite the increased 
pulillo~dry capillary wedge pressure with nitric oxide, arterial 
oxygen saturation remained >95% in all patienrs, in part 
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rr 3. Pubnonery vascular reristancc (PVR) at the time of initial 
evaluation (PRE) and 1 week postopcrativcly (1 WK POST) in the 
tients who have undergone heart wuwplantation. The mean 
) and SEM are also shown. 
because of concomitant administr;ltion of XH.l% oxygen. Mct- 
hemoglobin Ievvcls did not increase to >1.5% in any patient 
during nitric oxide administration. 
Clfnfenl outcome. In 13 of the 16 patients studied, pulmo- 
nary vascular resistance decreased to <200 dynesscm-’ with 
both nitroprusside and nitric oxide. In Patients 1 and 14, 
neither agent lowered pulmonaty vascular resistance to 
<200 dynessunnms. These patients were thought not to be 
suitable transplant recipients on the basis of these data, and 
they died of progressive heart failure. Patient 9, whose pulmo- 
nary vascular resistance decreased to 240 dynesscm-’ with 
nitroprusside and to 200 dynes-srm’-s with nitric oxide, under- 
went successful transplantation; his pulmonary vascular rcsis- 
tance was 146 dynes-s-cm-” 1 week postoperatively. 
In all, seven study patients have undergone transplanta- 
tion. Pulmonary vascular resistance decreased from 328 -c 
104 dynes%*m-s preoperatively to 157 z!z 18 dyness-cm+ 1 
week after transplantation (p C 0.05) (Fig. 3). There was no 
I change 4 weeks after transplantation. The decrease 
in pulmonary vascular resistance observed during inhalation of 
fJ0 ppm nitric oxide predicted the decrease measured 1 week 
after transplantation (Fig. 4A), as did the decrease in pulmo- 
nary vascular resistance observed with nitroprusside (Fig. 4B). 
‘Lvo patients (Patients 10 and ll), who had the highest 
preoperative pulmonary vascular resistance among those 
undergoing transplantation, were treated for early postopera- 
tive right heart failure with intravenous prostaglandin E, for 
the 1st 48 and 30 h, respectively. There were no deaths due to 
postoperative right heart failure, 
iscussion 
Elevation of left atrial pressure in chronic heart failure is 
associated with an obligatory increase in pulmonary artery 
pressure to maintain a pressure gradient for forward flow in 
the pulmonary circulation. Further elevation of pulmonary 
artery pressure results from pulmonary vasoconstriction. The 




0 20 40 80 80 100 
% DECREASE IN PVR WllM NRROPRUSSIDE 
@we 4. Correlation between the decrease in pulmonary vascular 
resistance (PVR) observed during inhalation of nitric oxide (A) or 
infusion of nitroprussidc (B) and that seen I week postoperatively in 
the seven patients who have undergone heart transplantation. PPM = 
parts per million by volume. 
presence of pulmonary hypertension is of importance to pa- 
tients undergoing heart transplantation because it is a risk 
factor for premature death in the postoperative period (1). The 
right ventricle of the donor heart undergoes ischemic injury 
during the harvesting and implantation procedures, making it 
particularly vulnerable to acute dysfunction and failure when 
confronted with an increase in afterload (19). Thus, patients 
with a fixed elevation of pulmonary vascuilar resistance are 
generally excluded as candidates for heart transplantation 
because of a high early postoperative mortality rate (2,3,20). 
Pulmonary hypertension caused by either an elevation in 
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ssure or arteriolar vasoconstr~ctio~ 
his observation 91 
utilize vasodilators such as nitro 
at patients whose pulmo- 
nary vascular resistance decreased to S-200 dynespcmm5 dur- 
ing nitroprusside infusion before transplantation had a mor- 
tality rate of oniy 4% at 3 months after tra~sp9a~tat~o~. Bn 
contrast. hose whose pulmonary vascular resistance could not 
be reduced to ~200 dynepscm-’ or could be so re 
at the expense of systemic ~~ypoteas~o~ bad a 3-mon 
ity of 41% and 28%, r 
er vas~~d~9ators have 
ate pulmonary vasoreactivity 
hypotension. ~rostag~a~di~ E, also caused ~i~~~~t~i~g systemic 
9iy~ote~~s~on at dosages required for adequate pulmonary 
v~is(~di9at~o~ ia patients with heart failure (6). Adcnosine 
decreased pulmonary vascular esistance witbout decreasing 
systemic arterial pressure in patients M~~der~oi~~8 evasuation for 
heart transplantation, but the degree of baseline pu9monary 
vasoconstriction f patients in this study was not in the range 
cons 
E 
circulations. Nitric oxide, an cndothelium-derived relaxation 
factor, causes vascular smooth muscle cell relaxation by acti- 
vating uanylate cyclasc, leadiag to an increase in ~ntracel~ulaF 
cyclic guanosine monophosphate (GMP) and reduction of 
intracellular calcium concentration (24,25). Because nitric 
oxide is rapidly bound to (26) and inactivated by (27) hemo- 
globin, inhaled nitric oxide might be expect be a selective 
pulmonary vasodilator. Previous tudies in ic sheep (IO). 
patients with primary pulmonary vclscular disease (15) and 
patients with pulmonary hypertension that was secondary to 
congenital heart disease (91) or chronic obstructive lung 
disease (28) or that persisted after cardiopulmonary b pass 
(29,30) have shown significant reductions in pulmonary vascu- 
lar resistance, without alterations insystemic arterial pressure, 
in response to nitric oxide at dosages ranging from 20 to 
80 ppm. 
The results of the present study extend to patients with 
chronic left heart failure the observation that nitric oxide 
decreases pulmonary vascular resistance without reducing sys- 
temic vascular esistance or mean systemic arterial pressure. 
The major effect of nitric oxide was a decrease in transpulmo- 
nary pressure gradient associated with an increase in pulmo- 
naly capillary wedge pressure without an equivalent increase in 
pulmonary artery pressure. In contrast, nitroprusside, a nitric 
oxide donor (31), caused a decrease in pulmonary vascular 
resistance associated with an increase in cardiac output with- 
out a change in transpulmonary pressure gradient; although 
pulmonary artery pressure decreased with nitroprusside, there 
was a corresponding decrease in pulmonary capillary wedge 
pressure. 
Furthermore, nitroprusside had, as expected, systemic he- 
reducing mean syst 
ic vascular ~~~~sta~~e 
n, while having a be 
tr~c~~ar performance through afterload reduction of the left 
ventricle, may have limited the dose of nitropmsside adminis. 
tered to the p~~rn~~a~ c~rc~lat~oa. Ths, the ratio of pulmo- 
nary vascular reSiStanCe to systemic vascular resistance did not 
change with nitroprusside, whereas it decreased by 40% with 
nitric oxide, demonstrating the selectivity of ~~baled nitric 
sure observed with 
doubtedly reflects an in- 
crease in left VentricM~ar end-diastolic pressure. Similarly, 
Haywood et al. (23) observed an increase in pulmonary 
ressure associated with a decrease in pulmo- 
ring infusion of adellosine in pa- 
here are several possible mecha- 
nisms for our observation: 9) There may have been increases in 
left ventricular end-systolic and end-diastolic volumes due to a 
negative inotropic effect of nitric oxide. The demonstration by
Finkel et al. (32) that inhibitors of nitric oxide synthase reverse 
the ability of pro-inflammatory c tokines to decrease contrac- 
tility in hamster papillary muscle supports uch a negative 
inotropic etiect. 2) Left ventricular preload may have increased 
in response to improved right ventricular pump function. 
These cllanges would be associated with an increase in left 
ventricular end-diastolic volume and pressure. Because strok.e 
volume was unaltered by nitric oxide in our study, this expla- 
nation is uniikeiy. 3) Left ventricular diastolic function may 
have been impaired without a change in Icft ventricular 
end-diastolic volume. It seems unlil<ely that an agent that 
increases intracellular cyclic GMP and decreases intracellular 
calcium would have a direct adverse ffect on myocardial 
relaxation. However, if inhalation of nitric oxide causes dila- 
tion and increased turgor of the coronary circulation, it could 
impair left ventricular compliance by this mechanism (33). 
Because nitric oxide is rapidly inactivated by hemoglobin (27), 
any effect of nitric oxide on the left ventricular myocardium or
the coronary circulation must be mediated by a metabolite or 
carrier molecule that preserves its biologic effect: Evidence has 
been presented for the existence of such molecules (34). 
Whatever the mechanism, the increase in left ventricular filling 
pressure seen during nitric oxide administration may limit its 
role to that of a diagnostic rather than a therapeutic agent in 
patients with severe heart failure. 
Clinical implications. Although controversy remains with 
regard to the level of pretransplantation pulmonary vasocon- 
striction beyond which the risk of right heart failure after 
transplantation is excessive, the study of Costard-llckle and 
Fowler (4) has established an acceptably ow risk in patients 
whose pulmonary vascular esistance is 1200 dynespcm ’
either at baseline or during administration of a dose : 
nitroprusside that does not induce systemic hypotension. in 
our study, 13 of 16 patients had this level of pulmonV 
vasodilation without systemic hypotension with either p:‘~ic 
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oxide or nitroprusside; 2 patients had pulnionary vasoconstric- 
tion that was not reversed by these agents; 1 patient (Patient 9) 
did not achieve the specified degree of pulmonary vasodilation 
with nitroprusside because administration of this agent was 
limited by systemic hypotension. His pulmonary vascular resis- 
tance did decrease satisfactorily with nitric oxide; he under- 
went heart transplantation without postoperative right heart 
failure and had a subsequent early decrease in pulmonary 
vascular resistance. Nitric oxide may thus have an important 
role in identifying potential heart transplant recipients in 
whom reversal of pulmonary vasoconstriction by nonselective 
vasodilators such as nitroprusside is limited by systemic hypo 
tension. Further studies enrolling greater numbers of patients 
with pulmonsry vasoconstriction that reverses with nitric oxide 
who ultimately undergo heart transplantation are necessary to 
test this hypothesis. In the seven patients who have thus far 
received a heart transplant, the decrease in pulmonary vascular 
resistance observed with inhaled nitric oxide during their initial 
evaluation did predict the decrease observed after transplan- 
tation. 
Summary. Inhaled nitric oxide is a selective pulmonary 
V ilator in patients with severe chronic heart failure. The 
selectivity of inhaled nitric oxide for the pulmonary circulation 
offers a potential advantage over nonselective vasodilators 
such as nitroprusside in the identification of reversible pulmo- 
nary vasoconstriction in potential heart transplant recipients. 
Nitric oxide increases left ventricular filling pressure in pa- 
tients with severe heart failure by an unknown mechanism. 
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